drugset / Trial / NCT00648778

Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg

NCT00648778

Phase 1 Completed 53 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan loxapine succinate 25 mg capsules to Watson Loxitane 25 mg capsules following a single, oral 25 mg (1 x 25 mg) dose administration under fasting conditions.

Timeline

Start
2003-01
Primary completion
2003-02
Completion
2003-02

Drugs

EvaluationDrugModalityDoseRoute
Subject loxapine Small molecule 25 mg Oral

Indications

No indication recorded.